drugset / Trial / NCT02269852
The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy seniors aged \> 60 years.
Timeline
- Start
- 2013-12
- Primary completion
- 2014-04
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anflu | Vaccine | 0.25 ml | — |
| Subject | Anflu | Vaccine | 0.5 ml | — |